British Biotech Signs Agreement with Glaxo Wellcome to Develop Oral Treatment for Arthritis

Strategic Insights -

British Biotech and Glaxo Wellcome have announced a significant agreement for the development of BB-2983, a novel oral treatment for arthritis. The deal marks a crucial step forward in bringing a potentially groundbreaking therapy to market. Under the agreement, Glaxo Wellcome will take over the development and marketing of BB-2983, with the first human trials expected to commence in the second half of 1996.

Key Takeaways:

  • British Biotech has signed an agreement with Glaxo Wellcome to develop BB-2983, a potential oral treatment for arthritis.
  • Glaxo Wellcome will fund all development costs for BB-2983 and receive exclusive worldwide rights to market the product, subject to regulatory approval.
  • British Biotech will receive royalties based on sales, with initial payments totaling 3 million pounds (US$4.7 million).
  • BB-2983 is a dual-action inhibitor of matrix metalloproteinase and tumor necrosis factor production, a new class of disease-modifying anti-inflammatory drugs known as TMIs.
  • The agreement allows for the development of BB-2983 or back-up compounds for inflammatory bowel disease and osteoporosis.
  • Dr. Keith McCullagh, British Biotech's chief executive, stated that the deal is an important example of the company's commitment to seeking pharmaceutical partners for the development and commercialization of its drugs.
  • Dr. James Niedel, Glaxo Wellcome's executive director, highlighted the need for effective treatments for arthritis and emphasized the company's commitment to developing BB-2983.

Statistics:

  • Initial payment to British Biotech: 3 million pounds (US$4.7 million)
  • Total funding for BB-2983 development: funded by Glaxo Wellcome
  • Expected completion date for preclinical development at British Biotech: late 1995
  • Expected start date for human trials: second half of 1996
  • Potential market for arthritis treatments: widespread condition affecting millions worldwide

Sources:

  • "British Biotech Announces Agreement with Glaxo Wellcome" (Business Wire, Sept. 27, 1995)
  • "BB-2983: A Novel Oral Treatment for Arthritis" (Technical Note, British Biotech)
  • Interviews with Dr. Keith McCullagh and Dr. James Niedel (as mentioned in the original text)